Enhancing our commitment to advancing cancer treatment
The Ravitz Foundation Phase 1 / Translational Research Center has begun enrolling volunteers in its first clinical trial. This new center enhances our commitment to advancing cancer treatment on two levels:
Second, the unit will help to speed these promising therapies from the laboratory to the clinic - where our patients may ultimately benefit.
Under the leadership of Moshe Talpaz, M.D., associate director of translational research and David Smith, M.D., clinical director of the Translational Research Center, the facility offers a comprehensive array of translational research resources to Cancer Center faculty as well as investigators at other academic institutions and pharmaceutical and biotechnology companies. To start, the center expects to handle about 10 clinical trials a year examining the effects of potential drugs and therapies that have never before been used in humans. The center is open to clinical trials for all types of cancer.
Patients who volunteer to participate in Phase 1 clinical trials are strictly monitored by faculty physicians, research nurses and data managers dedicated specifically to the center. The Phase 1 unit, which is located on the Cancer Center's second floor, offers four chairs and two beds for infusion as well as facilities for specialized patient monitoring.
Emulating the overall Cancer Center's commitment to bringing clinicians and researchers together in one space, the Phase 1 / Translational Research Center houses a laboratory equipped to provide a wide spectrum of services to assess the biological impact of potential therapies used in the clinic.
The Phase 1 / Translational Research Center offers the added benefit of streamlined regulatory and contractual processes. When an investigator initiates a new study with the center, the protocol review process is handled at the same time as study contract services negotiations. This process -- much of which is handled electronically -- can be completed in about two months.